| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 33 | 2023 | 1118 | 4.510 |
Why?
|
| Tumor Suppressor Protein p53 | 24 | 2023 | 289 | 3.560 |
Why?
|
| Mammary Glands, Animal | 19 | 2023 | 78 | 3.530 |
Why?
|
| Estrogens | 9 | 2022 | 109 | 2.390 |
Why?
|
| Mammary Neoplasms, Animal | 8 | 2022 | 29 | 2.260 |
Why?
|
| Mammary Glands, Human | 8 | 2019 | 53 | 2.180 |
Why?
|
| Li-Fraumeni Syndrome | 5 | 2023 | 7 | 1.920 |
Why?
|
| Mammary Neoplasms, Experimental | 8 | 2022 | 62 | 1.910 |
Why?
|
| Genes, p53 | 9 | 2023 | 52 | 1.670 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2020 | 474 | 1.440 |
Why?
|
| Receptors, Estrogen | 8 | 2023 | 124 | 1.210 |
Why?
|
| Mice, Inbred BALB C | 21 | 2021 | 868 | 1.160 |
Why?
|
| Progesterone | 6 | 2008 | 158 | 1.100 |
Why?
|
| Mice | 38 | 2023 | 10301 | 0.950 |
Why?
|
| Environmental Exposure | 4 | 2020 | 209 | 0.940 |
Why?
|
| Benzophenones | 3 | 2020 | 18 | 0.870 |
Why?
|
| Parabens | 2 | 2021 | 4 | 0.860 |
Why?
|
| Apoptosis | 7 | 2020 | 1033 | 0.840 |
Why?
|
| Animals | 48 | 2023 | 19667 | 0.810 |
Why?
|
| Quantitative Trait Loci | 4 | 2022 | 71 | 0.790 |
Why?
|
| Genes, Modifier | 1 | 2021 | 3 | 0.750 |
Why?
|
| Female | 53 | 2023 | 30766 | 0.740 |
Why?
|
| Laboratory Personnel | 1 | 2020 | 2 | 0.720 |
Why?
|
| Genetic Predisposition to Disease | 8 | 2023 | 676 | 0.710 |
Why?
|
| Laboratories | 1 | 2020 | 27 | 0.700 |
Why?
|
| DNA Breaks, Double-Stranded | 1 | 2021 | 78 | 0.700 |
Why?
|
| DNA Repair | 2 | 2021 | 242 | 0.690 |
Why?
|
| Gene Expression Regulation | 5 | 2021 | 1553 | 0.690 |
Why?
|
| Stem Cells | 2 | 2013 | 255 | 0.660 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 461 | 0.650 |
Why?
|
| Epithelial Cells | 10 | 2022 | 391 | 0.640 |
Why?
|
| DNA Replication | 1 | 2021 | 230 | 0.640 |
Why?
|
| Gene Expression Profiling | 7 | 2019 | 720 | 0.610 |
Why?
|
| Environmental Pollutants | 1 | 2020 | 91 | 0.610 |
Why?
|
| Transcriptome | 2 | 2019 | 341 | 0.600 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2019 | 152 | 0.590 |
Why?
|
| Mice, Knockout | 10 | 2021 | 1997 | 0.580 |
Why?
|
| Chromosome Mapping | 4 | 2021 | 284 | 0.560 |
Why?
|
| Parity | 2 | 2014 | 71 | 0.510 |
Why?
|
| Disease Models, Animal | 9 | 2021 | 2051 | 0.500 |
Why?
|
| Epithelium | 5 | 2010 | 96 | 0.460 |
Why?
|
| Membrane Proteins | 1 | 2019 | 850 | 0.430 |
Why?
|
| Receptors, Notch | 2 | 2011 | 101 | 0.420 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2013 | 29 | 0.410 |
Why?
|
| Estradiol | 2 | 2018 | 247 | 0.410 |
Why?
|
| Humans | 38 | 2023 | 59454 | 0.400 |
Why?
|
| Breast | 4 | 2020 | 174 | 0.400 |
Why?
|
| Cell Lineage | 1 | 2013 | 259 | 0.370 |
Why?
|
| Activins | 1 | 2011 | 54 | 0.360 |
Why?
|
| Lactation | 5 | 2023 | 66 | 0.350 |
Why?
|
| Genetic Linkage | 3 | 2021 | 93 | 0.350 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2021 | 440 | 0.350 |
Why?
|
| Tissue Transplantation | 1 | 2010 | 9 | 0.350 |
Why?
|
| Transforming Growth Factor beta | 3 | 2011 | 170 | 0.330 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 70 | 0.320 |
Why?
|
| Signal Transduction | 5 | 2019 | 2901 | 0.310 |
Why?
|
| Loss of Heterozygosity | 2 | 2010 | 24 | 0.310 |
Why?
|
| Prenatal Exposure Delayed Effects | 2 | 2021 | 151 | 0.310 |
Why?
|
| Cell Line, Tumor | 7 | 2023 | 1368 | 0.300 |
Why?
|
| Disease Susceptibility | 4 | 2021 | 157 | 0.300 |
Why?
|
| Heterozygote | 3 | 2007 | 162 | 0.290 |
Why?
|
| Mucins | 1 | 2007 | 25 | 0.280 |
Why?
|
| Pregnancy | 9 | 2023 | 2215 | 0.270 |
Why?
|
| Biosensing Techniques | 3 | 2017 | 113 | 0.270 |
Why?
|
| Neoplastic Stem Cells | 1 | 2008 | 196 | 0.270 |
Why?
|
| Recombination, Genetic | 3 | 2017 | 239 | 0.260 |
Why?
|
| Neoplasms | 5 | 2023 | 1232 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 3 | 2015 | 193 | 0.260 |
Why?
|
| Cyclins | 3 | 2002 | 40 | 0.240 |
Why?
|
| DNA Damage | 5 | 2008 | 279 | 0.240 |
Why?
|
| Transcription, Genetic | 1 | 2008 | 841 | 0.220 |
Why?
|
| Genes, p16 | 1 | 2003 | 6 | 0.210 |
Why?
|
| Sexual Maturation | 1 | 2023 | 51 | 0.210 |
Why?
|
| Phthalic Acids | 1 | 2023 | 36 | 0.210 |
Why?
|
| Germ-Line Mutation | 1 | 2023 | 43 | 0.210 |
Why?
|
| Risk Factors | 7 | 2019 | 4990 | 0.200 |
Why?
|
| Mitosis | 1 | 2004 | 209 | 0.200 |
Why?
|
| Adolescent | 5 | 2020 | 5851 | 0.200 |
Why?
|
| Immunoconjugates | 1 | 2023 | 85 | 0.200 |
Why?
|
| Receptors, Aryl Hydrocarbon | 1 | 2022 | 15 | 0.200 |
Why?
|
| Polychlorinated Biphenyls | 1 | 2022 | 39 | 0.190 |
Why?
|
| DNA-Binding Proteins | 3 | 2010 | 1151 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 2 | 2020 | 450 | 0.190 |
Why?
|
| Mice, Transgenic | 2 | 2002 | 1206 | 0.190 |
Why?
|
| Hormones | 1 | 2002 | 60 | 0.190 |
Why?
|
| Alleles | 1 | 2003 | 411 | 0.190 |
Why?
|
| Antineoplastic Agents | 2 | 2023 | 628 | 0.190 |
Why?
|
| Recombinational DNA Repair | 1 | 2021 | 19 | 0.180 |
Why?
|
| Genetic Loci | 1 | 2021 | 107 | 0.180 |
Why?
|
| Nanostructures | 1 | 2023 | 173 | 0.180 |
Why?
|
| Placental Hormones | 1 | 2000 | 1 | 0.170 |
Why?
|
| Macrophage Activation | 1 | 2020 | 118 | 0.170 |
Why?
|
| Toxicity Tests | 1 | 2020 | 17 | 0.170 |
Why?
|
| Gene Regulatory Networks | 2 | 2019 | 147 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 4 | 2017 | 52 | 0.160 |
Why?
|
| Prognosis | 3 | 2020 | 1597 | 0.160 |
Why?
|
| Sunscreening Agents | 1 | 2019 | 21 | 0.160 |
Why?
|
| Homeostasis | 1 | 2002 | 346 | 0.160 |
Why?
|
| Hyperplasia | 1 | 2019 | 85 | 0.160 |
Why?
|
| Cell Proliferation | 2 | 2020 | 942 | 0.160 |
Why?
|
| Cytoplasm | 1 | 2000 | 271 | 0.150 |
Why?
|
| Mitochondria | 2 | 2012 | 343 | 0.150 |
Why?
|
| Mammaplasty | 3 | 2014 | 43 | 0.150 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 750 | 0.150 |
Why?
|
| Adult | 7 | 2020 | 15697 | 0.140 |
Why?
|
| Middle Aged | 7 | 2020 | 16335 | 0.140 |
Why?
|
| Polymers | 3 | 2010 | 316 | 0.140 |
Why?
|
| Penaeidae | 1 | 2017 | 2 | 0.140 |
Why?
|
| Linkage Disequilibrium | 1 | 2017 | 46 | 0.140 |
Why?
|
| Rats | 4 | 2022 | 1911 | 0.140 |
Why?
|
| Bridged-Ring Compounds | 1 | 2017 | 7 | 0.140 |
Why?
|
| Selection, Genetic | 2 | 2017 | 71 | 0.140 |
Why?
|
| Mice, Inbred C57BL | 5 | 2017 | 3236 | 0.140 |
Why?
|
| Proto-Oncogene Proteins | 1 | 1999 | 318 | 0.140 |
Why?
|
| Neoplasm Proteins | 1 | 1999 | 278 | 0.140 |
Why?
|
| Endothelial Progenitor Cells | 1 | 2017 | 8 | 0.140 |
Why?
|
| Diabetic Angiopathies | 1 | 2017 | 24 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2000 | 323 | 0.140 |
Why?
|
| Luminescent Proteins | 1 | 2017 | 128 | 0.140 |
Why?
|
| Imidazoles | 1 | 2017 | 77 | 0.140 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2017 | 47 | 0.130 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2017 | 84 | 0.130 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2008 | 295 | 0.130 |
Why?
|
| Disease Progression | 2 | 2019 | 1119 | 0.130 |
Why?
|
| Young Adult | 4 | 2020 | 4274 | 0.130 |
Why?
|
| Cells, Cultured | 5 | 2021 | 2095 | 0.130 |
Why?
|
| Nanotechnology | 1 | 2017 | 127 | 0.130 |
Why?
|
| Genetic Variation | 1 | 2018 | 357 | 0.120 |
Why?
|
| Neoplasm Transplantation | 2 | 2010 | 161 | 0.120 |
Why?
|
| Ischemia | 1 | 2017 | 199 | 0.120 |
Why?
|
| Estrogen Receptor beta | 1 | 2015 | 23 | 0.120 |
Why?
|
| Mice, Mutant Strains | 2 | 2008 | 298 | 0.120 |
Why?
|
| Phenotype | 3 | 2017 | 1138 | 0.120 |
Why?
|
| Genes, Tumor Suppressor | 3 | 2014 | 70 | 0.120 |
Why?
|
| Oxidative Phosphorylation | 2 | 2012 | 39 | 0.120 |
Why?
|
| Genomics | 1 | 2017 | 322 | 0.120 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2015 | 83 | 0.110 |
Why?
|
| Energy Metabolism | 1 | 2017 | 359 | 0.110 |
Why?
|
| Metal Nanoparticles | 1 | 2017 | 182 | 0.110 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2014 | 13 | 0.110 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2017 | 588 | 0.110 |
Why?
|
| Organ Culture Techniques | 2 | 2005 | 68 | 0.110 |
Why?
|
| Pinctada | 1 | 2013 | 1 | 0.110 |
Why?
|
| Leukocytes | 1 | 2014 | 97 | 0.110 |
Why?
|
| Biomarkers | 1 | 2019 | 1306 | 0.110 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2013 | 122 | 0.100 |
Why?
|
| DNA Methylation | 1 | 2014 | 272 | 0.100 |
Why?
|
| Aging | 2 | 2012 | 710 | 0.100 |
Why?
|
| Prostatic Neoplasms | 1 | 2015 | 339 | 0.090 |
Why?
|
| Time Factors | 6 | 2019 | 3621 | 0.090 |
Why?
|
| 9,10-Dimethyl-1,2-benzanthracene | 2 | 2022 | 8 | 0.090 |
Why?
|
| Aged | 5 | 2020 | 13424 | 0.090 |
Why?
|
| Carcinogens | 2 | 2022 | 37 | 0.090 |
Why?
|
| Electron Transport Complex I | 1 | 2011 | 15 | 0.090 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2011 | 27 | 0.090 |
Why?
|
| Gamma Rays | 3 | 2011 | 31 | 0.090 |
Why?
|
| Calcium-Binding Proteins | 2 | 2010 | 87 | 0.090 |
Why?
|
| Dipeptides | 1 | 2011 | 60 | 0.090 |
Why?
|
| Amyloid Precursor Protein Secretases | 1 | 2011 | 69 | 0.090 |
Why?
|
| Stem Cell Transplantation | 1 | 2011 | 75 | 0.090 |
Why?
|
| Incidence | 3 | 2012 | 1239 | 0.090 |
Why?
|
| Mitogen-Activated Protein Kinase 9 | 1 | 2010 | 39 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2011 | 207 | 0.090 |
Why?
|
| Maternal Exposure | 2 | 2021 | 39 | 0.090 |
Why?
|
| Tumor Microenvironment | 1 | 2011 | 140 | 0.080 |
Why?
|
| Male | 9 | 2023 | 27784 | 0.080 |
Why?
|
| Mitogen-Activated Protein Kinase 8 | 1 | 2010 | 66 | 0.080 |
Why?
|
| Keratins | 1 | 2010 | 30 | 0.080 |
Why?
|
| Immunohistochemistry | 3 | 2009 | 851 | 0.080 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 49 | 0.080 |
Why?
|
| Endocrine Disruptors | 2 | 2021 | 73 | 0.080 |
Why?
|
| Gene Products, tat | 1 | 2009 | 14 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2010 | 194 | 0.080 |
Why?
|
| Fluorescence | 1 | 2010 | 83 | 0.080 |
Why?
|
| Fibroblasts | 2 | 2001 | 377 | 0.080 |
Why?
|
| Receptors, Progesterone | 1 | 2010 | 108 | 0.080 |
Why?
|
| Neoplasm Metastasis | 1 | 2009 | 186 | 0.080 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2008 | 15 | 0.080 |
Why?
|
| 14-3-3 Proteins | 1 | 2008 | 19 | 0.080 |
Why?
|
| Crosses, Genetic | 2 | 2007 | 105 | 0.070 |
Why?
|
| Placebos | 1 | 2008 | 68 | 0.070 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 98 | 0.070 |
Why?
|
| Ovariectomy | 1 | 2008 | 96 | 0.070 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2010 | 229 | 0.070 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 858 | 0.070 |
Why?
|
| Peptide Fragments | 1 | 2009 | 401 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 2010 | 428 | 0.070 |
Why?
|
| Gene Transfer Techniques | 1 | 2009 | 303 | 0.070 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 359 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2007 | 77 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2008 | 460 | 0.060 |
Why?
|
| Blotting, Northern | 1 | 2005 | 148 | 0.060 |
Why?
|
| Genotype | 1 | 2007 | 619 | 0.060 |
Why?
|
| Cloning, Organism | 2 | 2001 | 6 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2010 | 554 | 0.060 |
Why?
|
| Survival Rate | 1 | 2007 | 801 | 0.060 |
Why?
|
| Gene Expression | 2 | 2022 | 810 | 0.060 |
Why?
|
| Karyotyping | 1 | 2004 | 44 | 0.060 |
Why?
|
| Blotting, Southern | 1 | 2004 | 52 | 0.060 |
Why?
|
| Blotting, Western | 1 | 2005 | 584 | 0.060 |
Why?
|
| Mutation | 2 | 2011 | 2458 | 0.060 |
Why?
|
| Cell Division | 2 | 2002 | 443 | 0.050 |
Why?
|
| Inbreeding | 1 | 2003 | 5 | 0.050 |
Why?
|
| DNA-Activated Protein Kinase | 1 | 2003 | 12 | 0.050 |
Why?
|
| Genetic Vectors | 1 | 2009 | 808 | 0.050 |
Why?
|
| Nanoparticles | 1 | 2009 | 493 | 0.050 |
Why?
|
| Models, Biological | 1 | 2008 | 1143 | 0.050 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2003 | 51 | 0.050 |
Why?
|
| Molecular Structure | 2 | 2017 | 375 | 0.050 |
Why?
|
| Chromosomes | 1 | 2004 | 135 | 0.050 |
Why?
|
| Catalysis | 1 | 2023 | 152 | 0.050 |
Why?
|
| Cytochrome P-450 CYP1A1 | 1 | 2022 | 12 | 0.050 |
Why?
|
| Cell Cycle | 2 | 2001 | 383 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2003 | 185 | 0.050 |
Why?
|
| Rodentia | 1 | 2022 | 21 | 0.050 |
Why?
|
| Breast Density | 1 | 2022 | 16 | 0.050 |
Why?
|
| Chemoprevention | 1 | 2002 | 39 | 0.050 |
Why?
|
| Animals, Newborn | 1 | 2002 | 230 | 0.050 |
Why?
|
| Cell Nucleus | 2 | 2002 | 608 | 0.050 |
Why?
|
| Environment | 1 | 2022 | 119 | 0.050 |
Why?
|
| Nuclear Transfer Techniques | 1 | 2001 | 10 | 0.050 |
Why?
|
| Genes, BRCA1 | 1 | 2000 | 16 | 0.040 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2022 | 574 | 0.040 |
Why?
|
| Mice, Inbred Strains | 1 | 2000 | 180 | 0.040 |
Why?
|
| Gonadotropins, Equine | 1 | 2000 | 2 | 0.040 |
Why?
|
| Tissue Culture Techniques | 1 | 2020 | 31 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2023 | 487 | 0.040 |
Why?
|
| Embryo, Mammalian | 1 | 2001 | 156 | 0.040 |
Why?
|
| Chorionic Gonadotropin | 1 | 2000 | 14 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2023 | 244 | 0.040 |
Why?
|
| Cell Polarity | 1 | 2020 | 110 | 0.040 |
Why?
|
| Pituitary Gland | 1 | 2000 | 51 | 0.040 |
Why?
|
| Genitalia, Male | 1 | 2019 | 9 | 0.040 |
Why?
|
| Genitalia, Female | 1 | 2019 | 17 | 0.040 |
Why?
|
| Cell Line | 3 | 2011 | 1984 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2000 | 40 | 0.040 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2019 | 28 | 0.040 |
Why?
|
| Gene Deletion | 1 | 2000 | 293 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2019 | 46 | 0.040 |
Why?
|
| Genetic Code | 1 | 1999 | 6 | 0.040 |
Why?
|
| Drug Delivery Systems | 1 | 2023 | 312 | 0.040 |
Why?
|
| Puberty | 1 | 2019 | 58 | 0.040 |
Why?
|
| Anal Canal | 1 | 2019 | 34 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2014 | 1055 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 1999 | 32 | 0.040 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 1998 | 6 | 0.040 |
Why?
|
| Weaning | 1 | 1998 | 8 | 0.040 |
Why?
|
| In Situ Hybridization | 1 | 1998 | 214 | 0.040 |
Why?
|
| Alternative Splicing | 1 | 1999 | 122 | 0.040 |
Why?
|
| Research | 1 | 2019 | 188 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 1999 | 529 | 0.040 |
Why?
|
| Breeding | 1 | 2017 | 26 | 0.040 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 21 | 0.040 |
Why?
|
| Gene Ontology | 1 | 2017 | 38 | 0.040 |
Why?
|
| Pyruvic Acid | 1 | 2017 | 13 | 0.040 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2017 | 16 | 0.030 |
Why?
|
| Cell Respiration | 1 | 2017 | 21 | 0.030 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2017 | 21 | 0.030 |
Why?
|
| Molecular Sequence Annotation | 1 | 2017 | 62 | 0.030 |
Why?
|
| Hindlimb | 1 | 2017 | 44 | 0.030 |
Why?
|
| Metabolomics | 1 | 2017 | 49 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2002 | 1304 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 2017 | 108 | 0.030 |
Why?
|
| Menopause | 1 | 2019 | 249 | 0.030 |
Why?
|
| Neovascularization, Physiologic | 1 | 2017 | 101 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2017 | 304 | 0.030 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2017 | 190 | 0.030 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2017 | 264 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2017 | 516 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 197 | 0.030 |
Why?
|
| Computational Biology | 1 | 2017 | 334 | 0.030 |
Why?
|
| Gold | 1 | 2017 | 225 | 0.030 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 1097 | 0.030 |
Why?
|
| Binding Sites | 1 | 2017 | 881 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 1015 | 0.030 |
Why?
|
| Sex Factors | 1 | 2017 | 935 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2017 | 378 | 0.030 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2014 | 16 | 0.030 |
Why?
|
| DNA, Neoplasm | 1 | 2014 | 52 | 0.030 |
Why?
|
| Synteny | 1 | 2013 | 23 | 0.030 |
Why?
|
| Expressed Sequence Tags | 1 | 2013 | 27 | 0.030 |
Why?
|
| Microsatellite Repeats | 1 | 2013 | 38 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 245 | 0.030 |
Why?
|
| Carcinogens, Environmental | 1 | 2012 | 6 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1469 | 0.030 |
Why?
|
| Polymerase Chain Reaction | 1 | 2014 | 496 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2014 | 748 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 674 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2017 | 605 | 0.020 |
Why?
|
| Whole-Body Irradiation | 1 | 2011 | 33 | 0.020 |
Why?
|
| G1 Phase | 2 | 2001 | 55 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2011 | 52 | 0.020 |
Why?
|
| Radiation Chimera | 1 | 2011 | 57 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 59 | 0.020 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2011 | 53 | 0.020 |
Why?
|
| Reaction Time | 1 | 2011 | 119 | 0.020 |
Why?
|
| Cattle | 2 | 2001 | 304 | 0.020 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 635 | 0.020 |
Why?
|
| Discriminant Analysis | 1 | 2010 | 17 | 0.020 |
Why?
|
| Breast Neoplasms, Male | 1 | 2010 | 14 | 0.020 |
Why?
|
| Cysteine-Rich Protein 61 | 1 | 2009 | 4 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2009 | 73 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2009 | 137 | 0.020 |
Why?
|
| Wound Healing | 1 | 2009 | 174 | 0.020 |
Why?
|
| Base Sequence | 1 | 2011 | 1302 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 526 | 0.020 |
Why?
|
| Age Factors | 1 | 2012 | 1505 | 0.020 |
Why?
|
| Genome, Human | 1 | 2009 | 225 | 0.020 |
Why?
|
| Molecular Sequence Data | 1 | 2011 | 1953 | 0.020 |
Why?
|
| Transfection | 1 | 2009 | 675 | 0.020 |
Why?
|
| Specific Pathogen-Free Organisms | 1 | 2007 | 43 | 0.020 |
Why?
|
| Kidney | 1 | 2009 | 414 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 652 | 0.020 |
Why?
|
| Fenretinide | 1 | 2005 | 3 | 0.020 |
Why?
|
| Retinoid X Receptors | 1 | 2005 | 14 | 0.020 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2005 | 43 | 0.020 |
Why?
|
| Tretinoin | 1 | 2005 | 49 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 1560 | 0.010 |
Why?
|
| Ovary | 1 | 2005 | 98 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2005 | 365 | 0.010 |
Why?
|
| Cell Death | 1 | 2005 | 271 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2005 | 805 | 0.010 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 10 | 0.010 |
Why?
|
| Resting Phase, Cell Cycle | 1 | 2001 | 11 | 0.010 |
Why?
|
| Antimetabolites | 1 | 2001 | 17 | 0.010 |
Why?
|
| Bromodeoxyuridine | 1 | 2001 | 40 | 0.010 |
Why?
|
| Culture Techniques | 1 | 2001 | 12 | 0.010 |
Why?
|
| Cell Count | 1 | 2001 | 127 | 0.010 |
Why?
|
| S Phase | 1 | 2001 | 76 | 0.010 |
Why?
|
| Cell Survival | 1 | 2001 | 559 | 0.010 |
Why?
|